ZD-1-186

ZD-1-186 (50 μM; 24 h) potently inhibits MYC mRNA and protein levels, and induces the protein level of CDKN1A (p21) in HT diffuse large B-cell lymphoma cells, with minimal effects on cell viability at the tested concentration^[1].
ZD-1-186 (50 μM; 24 h) inhibits MYC protein levels and induces increased CDKN1A (p21) and BIM protein levels in SU-DHL-4 diffuse large B-cell lymphoma cells^[1].
The MYC inhibition and CDKN1A (p21) induction mediated by ZD-1-186 (50 μM; 24 h) are attenuated in a dose-dependent manner by pharmacological inhibition of BRD9 with BI-9564 in HT diffuse large B-cell lymphoma cells^[1].
The inhibitory effect of ZD-1-186 (50 μM; 24 h) on MYC in HT diffuse large B-cell lymphoma cells is attenuated by BRD9 knockout, whereas BRD9 knockout alone does not reduce MYC levels^[1].
ZD-1-186 (50 μM; 24 h) simultaneously relieves the repression of the canonical BCL6 inhibitory site and suppresses MYC-driven transcriptional programs in HT diffuse large B-cell lymphoma cells^[1].
ZD-1-186 (50 μM; 24 h) induces selective proximity binding between BCL6 and BRD9 in HEK293T cells^[1].
ZD-1-186 covalently binds to the C288 residue of BRD9, and competitively inhibits the labeling of BRD9 by cysteine-reactive probes in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.